TKB272
TKB272 is an orally active and selective antiviral agent targeting the main protease (Mpro) of SARS-CoV-2. It effectively blocks the infection and replication of various SARS-CoV-2 strains, including Omicron variants such as XBB.1.5 and EG.5.1. The enzymatic inhibitory activity of TKB272 shows an IC50 of 0.7 µM (against SARS-CoV-2WK-521 Mpro), and its antiviral activity at the cellular level reaches an EC50 as low as 2.6 nM (against BQ.1.1 strain in HeLahACE2-TMPRSS2 cells), with a cytotoxicity CC50 of 98 µM, indicating no apparent toxicity. In addition, TKB272 significantly suppresses the replication of SARS-CoV-2XBB.1.5 in B6.Cg-Tg (K18-hACE2) 2-Prlmn/J transgenic mouse models. TKB272 holds promise for research in the field of SARS-CoV-2 infection[1].
Product Specifications
CAS Number
2892688-18-3
UNSPSC
12352100
Target
SARS-CoV
Related Pathways
Anti-infection
Field of Research
Infection
Smiles
O=C(N[C@H](C(N1C[C@H](C2(C)C)[C@H]2[C@H]1C(N[C@H](C(C3=NC(C=C(F)C=C4)=C4S3)=O)C[C@@H]5CCNC5=O)=O)=O)C(C)(C)C)C(F)(F)F
Molecular Formula
C30H35F4N5O5S
Molecular Weight
653.69
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Escherichia coli Flagellar P-ring protein (flgI)